Concepedia

Christopher DesJardins

CD

7

Publications

402

Citations

7

H-Index

2009

Active since

Affiliations

Eisai (United States)(Current)

Andover Eye Associates

Eisai (Japan)

Medpace (United States)

Johns Hopkins University

Christopher DesJardins is an author at Eisai (United States) specializing in pharmacokinetics, drug discovery, and medicine.

Top concepts

Publications per year

2009–2017

7

Publications

7

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Sanjay Goel, Alain C. Mita, Monica Mita et al. · Clinical Cancer Research · 2009 · 144 citations

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

E. Anders Kolb, Richard Görlick, C. Patrick Reynolds et al. · Pediatric Blood & Cancer · 2013 · 87 citations · Full text

Peripheral Neuropathy Induced by Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term Recovery

Krystyna M. Wozniak, James J. Vornov, Ying Wu et al. · Cancer Research · 2017 · 58 citations · Full text

Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity

Krystyna M. Wozniak, James J. Vornov, Ying Wu et al. · Cancer Research · 2016 · 48 citations · Full text

Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice

Yanke Yu, Christopher DesJardins, Phil Saxton et al. · International Journal of Pharmaceutics · 2013 · 30 citations

, , +8

Rows per page

1–5 of 7